Smith & Nephew SNATS (SNN) – Research Analysts’ Recent Ratings Changes

Smith & Nephew SNATS (NYSE: SNN) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Smith & Nephew SNATS was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/15/2025 – Smith & Nephew SNATS was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating.
• 12/14/2025 – Smith & Nephew SNATS was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/6/2025 – Smith & Nephew SNATS was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 11/17/2025 – Smith & Nephew SNATS was upgraded by analysts at Kepler Capital Markets to a “strong-buy” rating.
• 11/11/2025 – Smith & Nephew SNATS had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $34.00. They now have a “hold” rating on the stock.

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.